GSK4184258A / GSK - LARVOL DELTA

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: GlaxoSmithKline | N=10 ➔ 40

Enrollment change • Infectious Disease • Novel Coronavirus Disease

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. (PubMed, Mol Ther) - P1 | "In hamsters, the vaccine candidate was well-tolerated, markedly reduced viral load in the upper and lower airways, and protected animals against disease in a dose-dependent manner, with no evidence of disease enhancement following SARS-CoV-2 challenge. Therefore, the SARS-CoV-2 SAM (LNP) vaccine candidate has a favorable safety profile, elicits robust protective immune responses against multiple SARS-CoV-2 variants, and has been advanced to Phase-1 clinical evaluation (NCT04758962)."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: GlaxoSmithKline; Recruiting ➔ Active, not recruiting; N=40 ➔ 10

Clinical • Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8